TASSINARI, ELISA
TASSINARI, ELISA
Borsisti
A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience
2024 Mollica, V.; Marchetti, A.; Fraccascia, N.; Nanni, C.; Tabacchi, E.; Malizia, C.; Argalia, G.; Rosellini, M.; Tassinari, E.; Paccapelo, A.; Fanti, S.; Massari, F.
Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report
2024 Casadio, Chiara; Tassinari, Elisa; Carloni, Riccardo; Rossi, Romina; Tenti, Maria Valentina; Fabbri, Laura; Maltoni, Marco
Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis
2024 Rosellini, Matteo; Mollica, Veronica; Marchetti, Andrea; Coluccelli, Sara; Giunchi, Francesca; Tassinari, Elisa; Ricci, Costantino; Fiorentino, Michelangelo; Tallini, Giovanni; De Biase, Dario; Massari, Francesco
Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma?
2024 Rosellini, Matteo; Marchetti, Andrea; Tassinari, Elisa; Mollica, Veronica; Massari, Francesco; Santoni, Matteo
Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma
2024 Mollica, Veronica; Rosellini, Matteo; Brocchi, Stefano; Galuppi, Francesco; Paccapelo, Alexandro; Tateo, Valentina; Marchetti, Andrea; Tassinari, Elisa; Mantuano, Francesco; Santoni, Matteo; Massari, Francesco
What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it?
2024 Tassinari, Elisa; Rosellini, Matteo; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco
An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma
2023 Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Tateo, Valentina; Nuvola, Giacomo; Rizzo, Alessandro; Massari, Francesco; Mollica, Veronica
Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis
2023 Santoni, Matteo; Rizzo, Alessandro; Kucharz, Jakub; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Tassinari, Elisa; Monteiro, Fernando Sabino Marques; Soares, Andrey; Molina-Cerrillo, Javier; Grande, Enrique; Battelli, Nicola; Massari, Francesco
How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma?
2023 Conci, Nicole; Tassinari, Elisa; Tateo, Valentina; Rosellini, Matteo; Marchetti, Andrea; Ricci, Costantino; Chessa, Francesco; Santoni, Matteo; Grande, Enrique; Mollica, Veronica; Massari, Francesco
Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study
2023 Rizzo, Alessandro; Mollica, Veronica; Tateo, Valentina; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; De Luca, Raffaele; Santoni, Matteo; Massari, Francesco
Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis
2023 Rizzo, Alessandro; Nuvola, Giacomo; Palmiotti, Gennaro; Ahcene-Djaballah, Selma; Mollica, Veronica; Rosellini, Matteo; Marchetti, Andrea; Nigro, Maria Concetta; Tassinari, Elisa; Macrini, Sveva; Massari, Francesco
Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report
2023 Elisa Tassinari, Nicole Conci, Giacomo Battisti, Francesco Porta, Valerio Di Scioscio, Maria Giulia Pirini, Dario de Biase, Maria Concetta Nigro, Miriam Iezza, Fausto Castagnetti, Luigi Lovato, Stefano Fanti, Maria Abbondanza Pantaleo, Margherita Nannini
Prostate cancer and novel pharmacological treatment options - what's new for 2022?
2023 Marchetti, Andrea; Tassinari, Elisa; Rosellini, Matteo; Rizzo, Alessandro; Massari, Francesco; Mollica, Veronica
Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial
2023 Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco
TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab
2023 Mollica, Veronica; Tassinari, Elisa; Santoni, Matteo; Marchese, Paola Valeria; Giunchi, Francesca; Maloberti, Thais; Tateo, Valentina; Ricci, Costantino; Rosellini, Matteo; Marchetti, Andrea; Fiorentino, Michelangelo; Biase, Dario De; Massari, Francesco
The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study
2023 Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Tateo, Valentina; Tassinari, Elisa; Rosellini, Matteo; Massafra, Raffaella; Santoni, Matteo; Massari, Francesco
A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy
2022 Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco
Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study
2022 Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; Myint Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F.
Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw
2022 Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.; Massari F.
Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer
2022 Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F.
| Titolo | Autore(i) | Anno | Periodico | Editore | Tipo | File |
|---|---|---|---|---|---|---|
| A prospective study on the early evaluation of response to androgen receptor-targeted agents with 11C-Choline, 68Ga-PSMA, and 18F-FACBC PET in metastatic castration-resistant prostate cancer: a single-center experience | Mollica, V.; Marchetti, A.; Fraccascia, N.; Nanni, C.; Tabacchi, E.; Malizia, C.; Argalia, G.; Ro...sellini, M.; Tassinari, E.; Paccapelo, A.; Fanti, S.; Massari, F. | 2024-01-01 | ESMO OPEN | - | 1.01 Articolo in rivista | ESMO Open 2024.pdf; appendix.docx |
| Appropriateness of Mini-Invasive Approaches for Nausea and Vomiting Refractory to Medical Therapy in Palliative Care Setting: A Case Report | Casadio, Chiara; Tassinari, Elisa; Carloni, Riccardo; Rossi, Romina; Tenti, Maria Valentina; Fabb...ri, Laura; Maltoni, Marco | 2024-01-01 | CASE REPORTS IN ONCOLOGY | - | 1.01 Articolo in rivista | 000536218.pdf; Supplementary_material-Suppl.1-s1.pdf |
| Chromosome 3p gene alterations as biomarkers for immunocombinations in metastatic renal cell carcinoma: A hypothesis-generating analysis | Rosellini, Matteo; Mollica, Veronica; Marchetti, Andrea; Coluccelli, Sara; Giunchi, Francesca; Ta...ssinari, Elisa; Ricci, Costantino; Fiorentino, Michelangelo; Tallini, Giovanni; De Biase, Dario; Massari, Francesco | 2024-01-01 | PATHOLOGY, RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| Do we need alternative PD-1 inhibitors for the treatment of renal cell carcinoma? | Rosellini, Matteo; Marchetti, Andrea; Tassinari, Elisa; Mollica, Veronica; Massari, Francesco; Sa...ntoni, Matteo | 2024-01-01 | EXPERT OPINION ON BIOLOGICAL THERAPY | - | 1.01 Articolo in rivista | - |
| Tumor growth rate to assess therapy response to immune-based combinations for metastatic renal cell carcinoma | Mollica, Veronica; Rosellini, Matteo; Brocchi, Stefano; Galuppi, Francesco; Paccapelo, Alexandro;... Tateo, Valentina; Marchetti, Andrea; Tassinari, Elisa; Mantuano, Francesco; Santoni, Matteo; Massari, Francesco | 2024-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | ERPMDD 2024 [TGR].pdf |
| What is the risk of hepatotoxicity induced by immune-checkpoint inhibitors and how can we avoid it? | Tassinari, Elisa; Rosellini, Matteo; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco | 2024-01-01 | EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY | - | 1.01 Articolo in rivista | - |
| An update on safety evaluation of immune-based combinations in patients with advanced renal cell carcinoma | Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Tateo, Valentina; Nuvola, Giacomo; Rizzo,... Alessandro; Massari, Francesco; Mollica, Veronica | 2023-01-01 | EXPERT OPINION ON DRUG SAFETY | - | 1.01 Articolo in rivista | - |
| Complete remissions following immunotherapy or immuno-oncology combinations in cancer patients: the MOUSEION-03 meta-analysis | Santoni, Matteo; Rizzo, Alessandro; Kucharz, Jakub; Mollica, Veronica; Rosellini, Matteo; Marchet...ti, Andrea; Tassinari, Elisa; Monteiro, Fernando Sabino Marques; Soares, Andrey; Molina-Cerrillo, Javier; Grande, Enrique; Battelli, Nicola; Massari, Francesco | 2023-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| How Do Molecular Classifications Affect the Neoadjuvant Treatment of Muscle-Invasive Urothelial Carcinoma? | Conci, Nicole; Tassinari, Elisa; Tateo, Valentina; Rosellini, Matteo; Marchetti, Andrea; Ricci, C...ostantino; Chessa, Francesco; Santoni, Matteo; Grande, Enrique; Mollica, Veronica; Massari, Francesco | 2023-01-01 | MOLECULAR DIAGNOSIS & THERAPY | - | 1.01 Articolo in rivista | Molecular Diagn Ther 2023 [Neoadj UC].pdf |
| Hypertransaminasemia in cancer patients receiving immunotherapy and immune-based combinations: the MOUSEION-05 study | Rizzo, Alessandro; Mollica, Veronica; Tateo, Valentina; Tassinari, Elisa; Marchetti, Andrea; Rose...llini, Matteo; De Luca, Raffaele; Santoni, Matteo; Massari, Francesco | 2023-01-01 | CANCER IMMUNOLOGY, IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Hypertransaminasemia in metastatic renal cell carcinoma patients receiving immune-based combinations: a meta-analysis | Rizzo, Alessandro; Nuvola, Giacomo; Palmiotti, Gennaro; Ahcene-Djaballah, Selma; Mollica, Veronic...a; Rosellini, Matteo; Marchetti, Andrea; Nigro, Maria Concetta; Tassinari, Elisa; Macrini, Sveva; Massari, Francesco | 2023-01-01 | IMMUNOTHERAPY | - | 1.01 Articolo in rivista | - |
| Metabolic pseudoprogression in a patient with metastatic KIT exon 11 GIST after 1 month of first-line imatinib: a case report | Elisa Tassinari, Nicole Conci, Giacomo Battisti, Francesco Porta, Valerio Di Scioscio, Maria Giul...ia Pirini, Dario de Biase, Maria Concetta Nigro, Miriam Iezza, Fausto Castagnetti, Luigi Lovato, Stefano Fanti, Maria Abbondanza Pantaleo, Margherita Nannini | 2023-01-01 | FRONTIERS IN ONCOLOGY | - | 1.01 Articolo in rivista | Tassinari, Conci Front Oncol 2023.pdf |
| Prostate cancer and novel pharmacological treatment options - what's new for 2022? | Marchetti, Andrea; Tassinari, Elisa; Rosellini, Matteo; Rizzo, Alessandro; Massari, Francesco; Mo...llica, Veronica | 2023-01-01 | EXPERT REVIEW OF CLINICAL PHARMACOLOGY | - | 1.01 Articolo in rivista | - |
| Re: Atezolizumab Plus Cabozantinib Versus Cabozantinib Monotherapy for Patients with Renal Cell Carcinoma After Progression with Previous Immune Checkpoint Inhibitor Treatment (CONTACT-03): A Multicentre, Randomised, Open-label, Phase 3 Trial | Rosellini, Matteo; Tassinari, Elisa; Marchetti, Andrea; Mollica, Veronica; Massari, Francesco | 2023-01-01 | EUROPEAN UROLOGY | - | 1.01 Articolo in rivista | - |
| TERT promoter mutations and the outcome of patients with advanced urothelial carcinoma treated by platinum-based chemotherapy or pembrolizumab | Mollica, Veronica; Tassinari, Elisa; Santoni, Matteo; Marchese, Paola Valeria; Giunchi, Francesca...; Maloberti, Thais; Tateo, Valentina; Ricci, Costantino; Rosellini, Matteo; Marchetti, Andrea; Fiorentino, Michelangelo; Biase, Dario De; Massari, Francesco | 2023-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| The impact of ECOG performance status on efficacy of immunotherapy and immune-based combinations in cancer patients: the MOUSEION-06 study | Mollica, Veronica; Rizzo, Alessandro; Marchetti, Andrea; Tateo, Valentina; Tassinari, Elisa; Rose...llini, Matteo; Massafra, Raffaella; Santoni, Matteo; Massari, Francesco | 2023-01-01 | CLINICAL AND EXPERIMENTAL MEDICINE | - | 1.01 Articolo in rivista | Clin Exp Med. 2023 [MOUSEION 06].pdf |
| A hypothesis-generating analysis on the role of TERT promoter mutation in advanced urothelial carcinoma treated with immunotherapy | Marchese, Paola Valeria; Mollica, Veronica; De Biase, Dario; Giunchi, Francesca; Tassinari, Elisa...; Marchetti, Andrea; Rosellini, Matteo; Nuvola, Giacomo; Maloberti, Thais; Fiorentino, Michelangelo; Massari, Francesco | 2022-01-01 | PATHOLOGY RESEARCH AND PRACTICE | - | 1.01 Articolo in rivista | - |
| Adjuvant PD-1 and PD-L1 Inhibitors and Relapse-Free Survival in Cancer Patients: The MOUSEION-04 Study | Rizzo A.; Mollica V.; Marchetti A.; Nuvola G.; Rosellini M.; Tassinari E.; Molina-Cerrillo J.; My...int Z.W.; Buchler T.; Monteiro F.S.M.; Grande E.; Santoni M.; Massari F. | 2022-01-01 | CANCERS | - | 1.01 Articolo in rivista | Cancers 2022 [MOUSEION04].pdf; cancers-14-04142-s001.zip |
| Bone Targeting Agents in Patients with Prostate Cancer: General Toxicities and Osteonecrosis of the Jaw | Mollica V.; Nuvola G.; Tassinari E.; Nigro M.C.; Marchetti A.; Rosellini M.; Rizzo A.; Errani C.;... Massari F. | 2022-01-01 | CURRENT ONCOLOGY | - | 1.01 Articolo in rivista | Current Oncology 2022 [Bone agents PCa].pdf |
| Guiding treatment selection with immunotherapy compared to targeted therapy agents in patients with metastatic kidney cancer | Rosellini M.; Marchetti A.; Tassinari E.; Nuvola G.; Rizzo A.; Santoni M.; Mollica V.; Massari F. | 2022-01-01 | EXPERT REVIEW OF PRECISION MEDICINE AND DRUG DEVELOPMENT | - | 1.01 Articolo in rivista | - |